Side-by-Side Comparison
Ozempic vs Wegovy
Same active ingredient (semaglutide), different FDA-approved indications. Ozempic for T2 diabetes; Wegovy for chronic weight management.
Same active ingredient (semaglutide), different FDA-approved indications. Ozempic for T2 diabetes; Wegovy for chronic weight management.
| Ozempic | Wegovy | |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| Approved indication | Type 2 diabetes (T2DM) | Chronic weight management; CV risk reduction in obesity + CVD |
| Initial FDA approval | December 5, 2017 | June 4, 2021 |
| Dose forms | Prefilled pen (multi-dose) | Single-dose vial + prefilled pen |
| Dose range | 0.25–2.4 mg weekly | 0.25–2.4 mg weekly |
| Insurance coverage | Often covered for T2DM with prior auth | Often covered for obesity with BMI documentation + step therapy |
| NovoCare cash pricing | Standard pen pricing | Reduced cash-pay on single-dose vials |
Ozempic and Wegovy are the same active drug — semaglutide — packaged and labeled separately for different FDA-approved uses. The molecule, dose, mechanism of action, and side-effect profile are identical. The split is regulatory: FDA approves a manufacturer's drug for a specific indication, and Lilly chose to brand the same molecule under two names. Some prescriptions can be substituted clinically but the labeling and insurance pathways are different.
Many commercial plans cover Ozempic for type 2 diabetes after step therapy through metformin and sometimes other agents. Many plans cover Wegovy for obesity with BMI documentation (BMI ≥30, or ≥27 with a weight-related comorbidity per the FDA label). Medicare Part D historically excluded obesity drugs but expanded Wegovy coverage for OSA in adults with obesity in 2025. Verify your specific plan's coverage rules.
Both list at approximately $1,000–$1,200/month before insurance. Novo Nordisk's NovoCare program (self-pay channel) offers reduced cash prices on Wegovy single-dose vials, which made the drug more accessible to cash-pay patients. Ozempic pricing via NovoCare varies by dose strength.
Compounded semaglutide is the same active molecule but is prepared by 503A licensed compounding pharmacies or 503B FDA-registered outsourcing facilities; it is not FDA-approved as a drug product and is not Ozempic or Wegovy. Telehealth providers (including SemaglutideGLPOne.com's #1 pick NexLife) typically dispense compounded versions at substantially lower cost than the brand-name products. Discuss with your clinician.
Identical for both brands since they contain the same active molecule: GI side effects (nausea most common), risk of pancreatitis, black-box warning for thyroid C-cell tumors (rodent studies). Contraindications: personal or family history of MTC, MEN 2, severe gastrointestinal disease, pregnancy, breastfeeding.
Are Ozempic and Wegovy the same drug?
Yes — both contain semaglutide, the same active molecule manufactured by Novo Nordisk. The FDA approved them under different brand names for different indications: Ozempic for type 2 diabetes (2022); Wegovy for chronic weight management (2021) and cardiovascular risk reduction in obesity + CVD (2024 label expansion).
Can I take Ozempic for weight loss?
Ozempic is FDA-approved only for type 2 diabetes. Off-label use for weight loss occurs but insurance typically denies obesity coverage for Ozempic because Wegovy is the on-label option. Discuss with a licensed clinician.
Which is cheaper, Ozempic or Wegovy?
Cash prices are similar at approximately $1,000–$1,200/month. Novo Nordisk's NovoCare program offers reduced cash pricing on Wegovy single-dose vials, which is often the lowest cash-pay option for the brand-name product. Compounded semaglutide via telehealth providers like NexLife is substantially less expensive ($145/month at NexLife's 12-month plan).
Compounded semaglutide · MD/DO oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000